Otonomy, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for otology in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. The company also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; and OTO- 313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. In addition, it develops OTO-413, a sustained exposure formulation of brain-derived neurotrophic factor for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties; OTO-5XX, an otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone619-323-2200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$750,000.00
Profitability
Miscellaneous
Employees49
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Otonomy (NASDAQ:OTIC) Frequently Asked Questions
What is Otonomy's stock symbol?
Otonomy trades on the NASDAQ under the ticker symbol "OTIC."
How were Otonomy's earnings last quarter?
Otonomy Inc (NASDAQ:OTIC) issued its quarterly earnings results on Monday, March, 4th. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the Zacks' consensus estimate of ($0.47) by $0.05. The biopharmaceutical company had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.18 million. Otonomy had a negative return on equity of 53.29% and a negative net margin of 6,760.81%. View Otonomy's Earnings History.
When is Otonomy's next earnings date?
What price target have analysts set for OTIC?
3 equities research analysts have issued twelve-month price targets for Otonomy's shares. Their predictions range from $5.00 to $10.00. On average, they expect Otonomy's stock price to reach $7.50 in the next year. This suggests a possible upside of 172.7% from the stock's current price. View Analyst Price Targets for Otonomy.
What is the consensus analysts' recommendation for Otonomy?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Otonomy.
What are Wall Street analysts saying about Otonomy stock?
Here are some recent quotes from research analysts about Otonomy stock:
- 1. According to Zacks Investment Research, "Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. The Company's product candidates under development includes AuriPro to treat pediatric patients with middle ear effusion; and OTO-104 for the treatment of patients with Ménière's disease. Otonomy, Inc. is headquartered in San Diego, California. " (3/9/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month price target of $5 per share on OTIC. On Monday, after market close, Otonomy reported 4Q18 revenues of $0.208M and cash of $97.3M. Our model projects current cash will provide two years of runaway (into 2021), which should include readout of the P3 study of OTIVIDEX for Ménière’s disease in 2020. We also expect to hear about" the initiation of a P1/2 study of OTO-313 for tinnitus in 2Q19 and a in hearing loss in 3Q19, with data from these two studies also expected in 2020. Questions on the call centered around the P3 OTIVIDEX study in which enrollment appears on track for study completion in 1H20." (3/4/2019)
Has Otonomy been receiving favorable news coverage?
Media coverage about OTIC stock has been trending neutral this week, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Otonomy earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the stock's share price in the next several days.
Who are some of Otonomy's key competitors?
Some companies that are related to Otonomy include MediciNova (MNOV), Osmotica Pharmaceuticals (OSMT), Karyopharm Therapeutics (KPTI), Insys Therapeutics (INSY), Kezar Life Sciences (KZR), Kindred Biosciences (KIN), American Brivision (Holding) (ABVC), Protagonist Therapeutics (PTGX), Geron (GERN), AC Immune (ACIU), Syros Pharmaceuticals (SYRS), Verrica Pharmaceuticals (VRCA), Minerva Neurosciences (NERV), Aduro BioTech (ADRO) and Merus (MRUS).
What other stocks do shareholders of Otonomy own?
Who are Otonomy's key executives?
Otonomy's management team includes the folowing people:
- Dr. Jay B. Lichter, Co-Founder & Chairman (Age 57)
- Dr. David Allen Weber, Pres, CEO & Director (Age 59)
- Mr. Paul E. Cayer, Chief Financial & Bus. Officer (Age 57)
- Dr. Kathie M. Bishop, Chief Scientific Officer (Age 53)
- Dr. Allen F. Ryan Ph.D., Co-Founder and Member of the Advisory Panel
Who are Otonomy's major shareholders?
Otonomy's stock is owned by a variety of of institutional and retail investors. Top institutional investors include First Manhattan Co. (9.93%), 683 Capital Management LLC (3.59%), Sofinnova Investments Inc. (3.34%), Pura Vida Investments LLC (2.93%), D. E. Shaw & Co. Inc. (2.81%) and BlackRock Inc. (2.75%). View Institutional Ownership Trends for Otonomy.
Which major investors are selling Otonomy stock?
OTIC stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Millennium Management LLC, Barclays PLC, D. E. Shaw & Co. Inc., Connor Clark & Lunn Investment Management Ltd. and Bank of America Corp DE. View Insider Buying and Selling for Otonomy.
Which major investors are buying Otonomy stock?
OTIC stock was acquired by a variety of institutional investors in the last quarter, including First Manhattan Co., Pura Vida Investments LLC, 683 Capital Management LLC, Sofinnova Investments Inc., BlackRock Inc. and Acadian Asset Management LLC. View Insider Buying and Selling for Otonomy.
How do I buy shares of Otonomy?
Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Otonomy's stock price today?
One share of OTIC stock can currently be purchased for approximately $2.75.
How big of a company is Otonomy?
Otonomy has a market capitalization of $84.37 million and generates $750,000.00 in revenue each year. The biopharmaceutical company earns $-50,370,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Otonomy employs 49 workers across the globe.
What is Otonomy's official website?
How can I contact Otonomy?
Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 619-323-2200 or via email at [email protected]
MarketBeat Community Rating for Otonomy (NASDAQ OTIC)
MarketBeat's community ratings are surveys of what our community members think about Otonomy and other stocks. Vote "Outperform" if you believe OTIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OTIC will underperform the S&P 500 over the long term. You may vote once every thirty days.
